Elliot Marseille

Abstract Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models is essential to ensuring that those most impacted have access to—and trust in—the treatments being developed.

A jar of iboga root powder is displayed in Akanda, Gabon, in February. Ibogaine, a compound made from the African root, has generated intriguing preliminary results as a treatment for fentanyl addiction. Nao Mukada/AFP via Getty Images Open-air drug markets. Bodies on sidewalks. Parents steering children around used needles. San Franciscans don’t need another explainer on the fentanyl epidemic — we’re living in one.

Mushrooms for patients are pictured at a psilocybin service center in Gresham, Ore., in November. Many people say taking tiny amounts of psilocybin mushrooms or LSD every few days boosts creativity, focus and mood. Craig Mitchelldyer/Associated Press Walk through any San Francisco coffee shop these days and you’ll likely overhear conversations about “microdosing” — taking tiny amounts of LSD or psilocybin mushrooms every few days to boost creativity, focus and mood.